Skip to content

NASDAQ · small · thesis board

PRTA Prothena

Anti-alpha-synuclein (prasinezumab) / neuro pipeline

View race

Thesis

Editorial summary — not a primary filing

Neuro programs including prasinezumab; partnered risk/reward profile.

Next gate

2027-05-01EstimatedPh2 readout

Partner update

261 days · Estimated: Estimated window

Survive-to-Event

ok

Cash covers the next gate with ~5 months spare (curated estimate).

Unverified estimate — not from a live SEC parse

Cash runway (~426d)100%
Days to gate (261d)61%
Show math

$420M cash ÷ $30M/mo burn ≈ 426 days. Source: curated SEC quarter figures.

Cash $420M as of 2026-03-31 (SEC)

Pipeline spine

  1. Preclinical
  2. Ph1
  3. Ph2
  4. Ph3
  5. Filed
  6. Approved

Rivals in this race

Open race →
SNYFiledokRHHBYPh3okNVSPh3ok

Risks

  • Partner decisions
  • Endpoint risk
  • Cash burn
  • Competitive neuro field

Source trail

  1. SECCash from latest reported quarter (curated)as of 2026-03-31
  2. ClinicalTrials.govNCT03100149as of 2026-07-01
  3. CompanyIR / press disclosuresas of 2026-07-01